商业广告

发表于2018年8月31日by Delveinsight

 阿斯特拉

NICE Rejects 吉利德科学公司 Yescarta on Cost Concerns

英国政府资助的医疗服务并不太好 Gilead Sciences’ CAR-T血癌治疗Yescarta。该国的国家卫生保健卓越研究所(NICE)说 这种疗法对于机构来说太昂贵了。英国机构的公告是在Yescarta(axicabtagene ciloleucel)获得批准后的一天 from the 欧洲药品管理局(EMA) 在整个欧盟使用。 Yescarta是欧洲首个获准用于两种类型的侵袭性非霍奇金病的CAR-T治疗药物’s Lymphoma. In the United States, treatment 与 Yescarta 具有 a list price of about $373,000. It was first approved in the U.S. in October 2017.

塞拉利昂肿瘤学获得吉利德停转的骨髓纤维化药物 莫洛替尼

Sierra 具有 acquired the drug, momelotinib, from Gilead, for $3 million up front. The deal adds a late-stage drug candidate to Sierra’s pipeline of early-stage 癌症 drugs. Meanwhile, Gilead, gains a way to salvage something 来自 $510 million 收购YM Biosciences 在2012年,它带来了莫莫替尼。如果塞拉利昂能够将这种药物推向市场,吉利德将获得高达1.95亿美元的里程碑付款以及销售特许权使用费。

Evotec和Novo Nordisk Ink达成开发肥胖症和糖尿病药物的协议

与合作伙伴后的几个月 Sanofi 关于传染病,Evotec has 建立了另一个重要的伙伴关系 with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases. Evotec will apply its ligand-based drug discovery design program to select safe and efficacious products that can then be used to address diabetes and associated morbidities. When the preclinical candidates are selected, Novo Nordisk will use the German company’s INDiGo platform to take those preclinical candidates into the clinic. Novo Nordisk 具有 a successful track record and proven leadership in developing treatments for diabetes and obesity. Evotec did not disclose any financial details of the agreement 与 Novo Nordisk.

(造访13次,今天造访1次)